Exscientia plc (NASDAQ:EXAI - Get Free Report) shares saw strong trading volume on Tuesday . 565,029 shares traded hands during trading, a decline of 11% from the previous session's volume of 637,333 shares.The stock last traded at $5.17 and had previously closed at $5.56.
Analyst Ratings Changes
EXAI has been the subject of a number of recent research reports. Barclays reissued an "equal weight" rating and set a $5.00 price objective on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen restated a "hold" rating on shares of Exscientia in a research report on Friday, August 9th.
Read Our Latest Research Report on Exscientia
Exscientia Stock Down 11.7 %
The company's 50-day simple moving average is $5.33 and its two-hundred day simple moving average is $5.35. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The firm has a market capitalization of $593.56 million, a P/E ratio of -3.66 and a beta of 0.85.
Exscientia (NASDAQ:EXAI - Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05). The business had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. As a group, research analysts expect that Exscientia plc will post -1.25 earnings per share for the current year.
Hedge Funds Weigh In On Exscientia
Large investors have recently made changes to their positions in the company. Novo Holdings A S acquired a new stake in shares of Exscientia in the second quarter valued at about $66,742,000. Bank of New York Mellon Corp grew its stake in Exscientia by 108.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company's stock worth $1,981,000 after purchasing an additional 202,377 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Exscientia in the 2nd quarter valued at $256,000. Federated Hermes Inc. acquired a new position in Exscientia in the second quarter valued at approximately $115,000. Finally, New Republic Capital LLC purchased a new position in shares of Exscientia during the fourth quarter worth about $128,000. 41.58% of the stock is currently owned by institutional investors and hedge funds.
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Featured Articles
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
